Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $4.1 million.

  • Vanda Pharmaceuticals' Change in Receivables fell 803.43% to $4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.5 million, marking a year-over-year decrease of 4264.53%. This contributed to the annual value of $7.5 million for FY2025, which is 4264.53% down from last year.
  • Vanda Pharmaceuticals' Change in Receivables amounted to $4.1 million in Q4 2025, which was down 803.43% from $5.6 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Change in Receivables ranged from a high of $9.1 million in Q2 2023 and a low of -$9.0 million during Q4 2021
  • Over the past 5 years, Vanda Pharmaceuticals' median Change in Receivables value was $2.0 million (recorded in 2021), while the average stood at $1.2 million.
  • Examining YoY changes over the last 5 years, Vanda Pharmaceuticals' Change in Receivables showed a top increase of 66242.27% in 2023 and a maximum decrease of 82984.82% in 2023.
  • Vanda Pharmaceuticals' Change in Receivables (Quarter) stood at -$9.0 million in 2021, then surged by 145.16% to $4.1 million in 2022, then rose by 18.79% to $4.8 million in 2023, then fell by 8.37% to $4.4 million in 2024, then fell by 8.03% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q4 2025, $5.6 million for Q3 2025, and $353000.0 during Q2 2025.